The Influenza Diagnostics Market is expected to grow at a CAGR of 7.9% from 2020 to 2027 to reach at $1.17 billion by 2027.
Influenza which is commonly known as “the flu”, is an infectious disease caused by an influenza virus. It is spread in all population more specifically in people with weak immune response. Efforts made to reduce or eradicate the occurrence of the remerging influenza among the population worldwide led to the development of new diagnostic methods.
Increasing prevalence of influenza, growing awareness for early detection using specific diagnostic tests, development of CLIA-waived POC molecular influenza tests, and shifting focus from centralized laboratories to decentralized point-of-care testing are some of the key factors driving the growth of the global influenza diagnostics market.
Here are the top 10 companies operating in the global influenza diagnostics Market.
Founded in 2006 and headquartered at Massachusetts; U.S.; Thermo Fisher Scientific is a biotechnology company primarily engaged in accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics, and increasing laboratory productivity. The company operates through its four reportable business segments, namely, Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. Through its Life Sciences Solutions segment, the company provides an extensive range of reagents, instruments and consumables used in biological and medical research, discovery, and production of new drugs and vaccines. The Analytical Instruments segment provides instruments, consumables, software, and services that are used for a range of applications in the laboratory. The company’s Specialty Diagnostics segment offers a wide range of diagnostic test kits, reagents, culture media, instruments, and associated products in order to serve customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. The Laboratory Products and Services segment offers virtually everything needed for the laboratory. The company provides products for the influenza disease diagnostics market through its Specialty Diagnostics segment.
The company’s Specialty Diagnostics business segment has a direct presence in the U.S. through its operational offices, engineering sites, and laboratories; and production sites which are present in Virginia, Kansas, Michigan, New Hampshire, and California, within the U.S., and in Sweden, Germany, the U.K., France, Switzerland, Finland, China, Canada, and Japan.
Founded in 1888 and headquartered at Illinois, U.S.; Abbott is majorly engaged in the discovery, development, manufacturing, and sale of a comprehensive range of healthcare products. The company offers a wide range of products in diagnostics, medical devices, nutrition, and branded generic pharmaceuticals markets. The company operates through four reportable business segments, namely, Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers products for influenza disease diagnosis through its Diagnostic Products business segments. This segment includes core laboratory systems, molecular diagnostics systems, point of care systems, rapid diagnostics systems, and informatics and automation solutions.
The company has a wide geographic presence in countries such as Germany, Japan, India, Switzerland, Russia, France, Brazil, Italy, the U.K., the U.S., the Netherlands, Colombia, Vietnam, and other countries. The company operates through its 100 manufacturing facilities in 32 countries across the globe. The company has 28 manufacturing sites worldwide for developing diagnostic products. The subsidiaries of the company operating in the infectious disease control market areal ere Inc. (U.S.), Abbott Laboratories Inc. (U.S.), Abbott Laboratories Argentina SociedadAnónima (Argentina), Alere GmbH (Austria), Abbott International Corporation (Canada), Abbott Laboratories (Chile) Holdco (Dos) SpA (Chile), Abbott Laboratories Trading (Shanghai) Co., Ltd. (China), Abbott Laboratories de Colombia, S.A (Colombia), Alere Diagnostics GmbH (Germany), Abbott Laboratories Limited (Hong Kong), Abbott Laboratories, Ireland, Limited (Ireland), Abbott Laboratories (Singapore) Private Limited (Singapore), Abbott Laboratories, S.A. (Spain), Abbott Laboratories Limited (Thailand), and Abbott Laboratories Trustee Company Limited (U.K.).
Founded in 1969 and headquartered at Washington, U.S.; Danaher is primarily involved in designing, manufacturing, and marketing medical, professional, industrial, and commercial products and services for various end users. The company operates through four reportable business segments, namely, Life Sciences; Diagnostics; Dental; and Environmental & Applied Solutions. Danaher offers its products and services in the influenza disease diagnostics market through its Diagnostics segment. The company’s Diagnostics segment primarily offers analytical instruments, reagents, consumables, software, and services to help hospitals, physicians’ offices, reference laboratories, and other critical care settings to diagnose disease and make treatment decisions.
The company’s research and development, manufacturing, sales, distribution, service, and administrative facilities are located in more than 60 countries across the globe. The company has established its presence in the U.S., China, Germany, Japan, and other countries. Its manufacturing facilities for the Diagnostic business segment are majorly located in North America, Europe, Asia, and Australia. The company sells its products through direct sales personnel and independent distributors. The subsidiary operating in the influenza diagnostics market is Cepheid (U.S.).
Founded in 1952 and headquartered at California, U.S., Bio-Rad is primarily engaged in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. The company manufactures and supplies a wide array of products and systems to separate complex chemical and biological materials and to identify, analyze, and purify their components. The products of the companies are majorly used by various end users engaged with life science research, healthcare, and analytical chemistry. The company operates through two reportable segments—Life Science and Clinical Diagnostics. The company provides products for influenza disease diagnosis through its Clinical Diagnostics segment. This segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls that serve clinical laboratories in the global diagnostics market.
The company has a direct presence through its manufacturing, research, and distribution facilities in the U.S., France, Switzerland, Germany, Belgium, Switzerland, and Singapore. The company also has direct distribution channels in over 35 countries through subsidiaries, distributors, and agents. The principal manufacturing and research facilities of the company for the Clinical Diagnostics segment is located in the U.S., Singapore, France, Switzerland, Germany, and Belgium.
Founded in 1963 and headquartered at I’Etoile, U.S.; bioMérieux manufactures in-vitro diagnostic solutions and is engaged in the development of new approaches in the field of diagnostics, immunotherapy, food safety, and nutrition to fight against infectious diseases and cancers. The company develops, manufactures, and markets systems that are used in Industrial and Clinical Applications i.e. for clinical diagnostics, industrial microbiological control – particularly in the agri-food sector, environmental monitoring, veterinary diagnostics, microbial identification, and resistance detection. The company offers various solutions such as antimicrobial resistance management, C. difficile infection management, HIV diagnostics & management, emergency department patient management, lab efficiency, and sepsis.Based on the application areas, the company reports its revenue under Microbiology, Immunoassays, Molecular Biology, Industrial Applications, and Other Lines, including testing services for customers.
The company has a direct presence through its production and R&D sites in the U.S., Brazil, France, Spain, Italy, Australia, Germany, India, Belgium, and China and through its subsidiaries in Kenya, the U.S, Norway,Serbia,Chile, Mexico, Brazil, Sweden, Argentina, Vietnam, Thailand, India, China, Canada, Turkey, Russia, Italy, Greece, Germany, Belgium, Singapore, Japan, the U.K., Australia, Spain, the Netherlands, and South Africa.
Founded in 1896 and headquartered in Basel, Switzerland; F. Hoffmann-La Roche is a research-based healthcare company. The company is majorly engaged in creating innovative medicines and providing solutions for diagnostics tests to help the unmet need of the customers worldwide. The company operates through two major business segments, namely, Pharmaceuticals and Diagnostics. The company’s Diagnostic division consists of three business areas —centralized and point of care solutions, molecular diagnostics, and diabetes care. The Diagnostic business division manufactures equipment and reagents for research and medical diagnostic applications.
The company has its major geographic presence in North America, Europe, Asia, Latin America, Africa, Australia, and New Zealand. The company has 26 manufacturing sites and 30 R&D sites for its pharmaceutical and diagnostics businesses across the globe.
Founded in 1897 and headquartered at New Jersey, U.S.; Becton, Dickinson and Company (BD) is a global medical technology company. The company is primarily engaged in the development, manufacturing, and sale of a comprehensive range of medical supplies, devices, laboratory equipment, and diagnostic products. The company primarily operates through three business segments, namely, BD Medical, BD Life Sciences, and BD Interventional.
The company provides influenza disease diagnostic products through its BD Life Sciences business segment. In October 2019, BD Life Sciences joined its Preanalytical Systems and Diagnostic Systems organizational units to create a new Integrated Diagnostic Solutions organizational unit focusing on driving growth and innovation for diagnostic solutions. The Integrated Diagnostic Solutions segment comprises of integrated systems for specimen collection, automated blood culturing and tuberculosis culturing systems, molecular testing systems for infectious diseases and women’s health, microorganism identification and drug susceptibility systems, and others. The primary customers served by the BD Life Sciences segment are hospitals, laboratories and clinics, blood banks, healthcare workers, public health agencies, physicians’ office practices, retail pharmacies, academic and government institutions, and pharmaceutical and biotechnology companies.
The company manufactures and sells its products in the U.S., Europe, the Middle East, Greater Asia, Latin America, and Canada. The company has a wide distribution network across the globe. It markets its products through independent distribution channels and directly to hospitals, other healthcare institutions, and independent sales representatives. As of September 2019, the company had a headcount of 70,093 employees, of which 24,191 were employed in the U.S.
Founded in 1977 and headquartered at Ohio, U.S.; Meridian Bioscience is a fully integrated life science company primarily engaged in the development, manufacture, sale, and distribution of diagnostic test kits, bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents. The company operates through two primary reportable segments, namely, Diagnostics and Life Science.
The company provides a broad spectrum of clinical diagnostic products, testing platforms, and technologies used to serve acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories in over 70 countries across the world. The company’s Life Science segment focuses on the development, manufacture, sale, and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents majorly used by researchers, agri-bio companies, and other diagnostic manufacturing companies.
The company majorly provides products required in the influenza disease diagnostics market through its Diagnostics business segment. In June 2019, the company acquired GenePOC Inc. (Canada) to strengthen its molecular diagnostic assays and instruments portfolio. This acquisition helped the company to sell its molecular assay products through the Revogene brand.
The company’s Diagnostic business segment has a major geographic presence in the U.S., Italy, Japan, France, the U.K., Belgium, and the Netherlands. The company’s infectious disease manufacturing and R&D sites are located in Ohio, U.S. Its blood-chemistry manufacturing and R&D operations are located in Massachusetts, U.S., and PCR-based molecular manufacturing and R&D operations are located in Quebec City, Canada. The company has its diagnostic products centers across the Americas, Europe, and the Middle East and Africa (EMEA).
Founded in 1979 and headquartered at California, U.S. Quidel is a healthcare manufacturer majorly engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The diagnostic testing solutions provided by the company are separated into four product categories, such as rapid immunoassays, cardiac immunoassays, specialized diagnostic solutions, and molecular diagnostic solutions. Quidel serves a wide array of end users with its products, including physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail clinics, pharmacies, and wellness screening centers. The company offers influenza disease diagnosis products through three categories—rapid immunoassays, specialized diagnostic solutions, and molecular diagnostic solutions.
Quidel sells its products in approximately 90 countries worldwide. The company has three primary manufacturing sites. Two are in San Diego, California, and one in Athens, Ohio. Quidel distributes its products through a network of distributors or direct sales.
Founded in 1985 and headquartered at Massachusetts, U.S.; Hologic is engaged in developing, manufacturing, and supplying diagnostic products, medical imaging systems, and surgical products. The company operates through five business segments, namely, Diagnostic, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health. The company provides influenza diagnostic products through its Diagnostic segment. The primary diagnostics products under the Diagnostics segment include the Aptima family of molecular diagnostic assays, which run on its advanced instrumentation systems like Panther and Tigris, ThinPrep cytology system, and the Rapid Fetal Fibronectin Test. The Aptima portfolio also includes diagnostic tests for a range of acute respiratory ailments that run on the Panther Fusion system, a field-upgradeable instrument addition to Panther
With its subsidiaries and a strong network of distribution, the company has its presence in the U.S., France, the U.K., Germany, China, Australia, Japan, Canada, Latin America, and the Middle East. The company has its manufacturing facilities in the U.S., Germany, the U.K., and Northern Ireland and has leased various administrative and customer support centers in Belgium, Spain, China, and Germany.
Authoritative Research on the Influenza Diagnostics Market – Global Opportunity Analysis and Industry Forecast (2020-2027)
Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:
- Recent financial performance
- Key products
- Significant company strategies
- Partnerships and acquisitions
The Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.
Please download report pages and learn more: https://www.meticulousresearch.com/download-sample-report/cp_id=5099